Synthesis of 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus

Antiviral Research

Volumn 79, Issue 1, 2008, Pages 19-27

  Chung, Dong Hoon ^a   Kumarapperuma, Sidath C ^b   Sun, Yanjie ^a   Li, Qianjun ^a   Chu, Yong Kyu ^a   Arterburn, Jeffrey B ^b   Parker, William B ^a   Smith, Jeffrey ^c   Spik, Kristin ^c   Ramanathan, Harish N ^d   Schmaljohn, Connie S ^c   Jonsson, Colleen B ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Andes virus; Crimean Congo hemorrhagic fever virus; Hantaan virus HTNV; Hemorrhagic fever with renal syndrome; HFRS; Ribavirin; Rift Valley fever virus

Indexed keywords

1 BETA DEXTRO RIBOFURANOSYL 3 ETHYNYL [1,2,4]TRIAZOLE; 1,2,4 TRIAZOLE DERIVATIVE; 5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; MYCOPHENOLIC ACID; RIBAVIRIN;

ANDES VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BUNYAVIRUS; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER VIRUS; DISEASE COURSE; DRUG STRUCTURE; DRUG SYNTHESIS; HANTAVIRUS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER BUNYAVIRUS; VIRUS HEMORRHAGIC FEVER;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; FEMALE; GENOME, VIRAL; GUANOSINE; GUANOSINE TRIPHOSPHATE; HANTAVIRUS; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HUMANS; MICE; MICE, INBRED STRAINS; MUTATION; NUCLEOSIDES; RIBAVIRIN; TRIAZOLES; VERO CELLS;

ANDES VIRUS; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; HANTAAN VIRUS; HANTAVIRUS; MUS; RIFT VALLEY FEVER VIRUS;

EID: 43149119012     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.02.003     Document Type: Article

References (42)

1. Andrei G., and De Clercq E. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antivir. Res. 22 (1993) 45-75
2. Balzarini J., Stet L., Matsuda A., Wiebe L., Knauss E., and De Clercq E. Metabolism of EICAR (5-ethynyl-1-beta-d-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase. Adv. Exp. Med. Biol. 431 (1998) 723-728
3. Bangash S.A., and Khan E.A. Treatment and prophylaxis with ribavirin for Crimean-Congo Hemorrhagic Fever--is it effective?. J. Pak. Med. Assoc. 53 (2003) 39-41
4. Botten J., Mirowsky K., Kusewitt D., Bharadwaj M., Yee J., Ricci R., Feddersen R.M., and Hjelle B. Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). PNAS 97 (2000) 10578-10583
5. Botten J., Mirowsky K., Ye C., Gottlieb K., Saavedra M., Ponce L., and Hjelle B. Shedding and intracage transmission of Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus) model. J. Virol. 76 (2002) 7587-7594
6. Bronze M.S., and Greenfield R.A. Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr. Opin. Investig. Drugs 4 (2003) 172-178
7. Browne M.J. Mechanism and specificity of action of ribavirin. Antimicrob. Agents Chemother. 15 (1979) 747-753
8. Chaparro J., Vega J., Terry W., Vera J.L., Barra B., Meyer R., Peters C.J., Khan A.S., and Ksiazek T.G. Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. J. Hosp. Infect. 40 (1998) 281-285
9. Chapman L.E., Mertz G.J., Peters C.J., Jolson H.M., Khan A.S., Ksiazek T.G., Koster F.T., Baum K.F., Rollin P.E., Pavia A.T., Holman R.C., Christenson J.C., Rubin P.J., Behrman R.E., Bell L.J., Simpson G.L., Sadek R.F., and Ribavirin Study Group. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir. Ther. 4 (1999) 211-219
10. Chung D.H., Sun Y., Parker W., Arterburn J., Bartolucci A., and Jonsson C.B. Ribavirin reveals a lethal threshold of allowable mutation frequency for hantaan virus. J. Virol. 81 (2007) 11722-11729
11. Compton S.R., Jacoby R.O., Paturzo F.X., and Smith A.L. Persistent Seoul virus infection in Lewis rats. Arch. Virol. 149 (2004) 1325-1339
12. De Clercq E. Recent highlights in the development of new antiviral drugs. Curr. Opin. Microbiol. 8 (2005) 552-560
13. Enria D., Padula P., Segura E.L., Pini N., Edelstein A., Posse C.R., and Weissenbacher M.C. Hantavirus pulmonary syndrome in Argentina. Possibility of person to person transmission. Medicina (B Aires) 56 (1996) 709-711
14. Eriksson B., Helgstrand E., Johansson N.G., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S., and Oberg B. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11 (1977) 946-951
15. Ferm V.H., Willhite C., and Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17 (1978) 93-101
16. Goswami B.B., Crea R., Van Boom J.H., and Sharma O.K. 2′-5′-Linked oligo(adenylic acid) and its analogs. A new class of inhibitors of mRNA methylation. J. Biol. Chem. 257 (1982) 6867-6870
17. Goundry W.R.F., Baldwin J.E., and Lee V. Total synthesis of cytotoxic sponge alkaloids hachijodines F and G. Tetrahedron 59 (2003) 1719-1729
18. Graci J.D., and Cameron C.E. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16 (2006) 37-48
19. Harvie P., Omar R.F., Dusserre N., Desormeaux A., Gourde P., Tremblay M., Beauchamp D., and Bergeron M.G. Antiviral efficacy and toxicity of ribavirin in murine acquired immunodeficiency syndrome model. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12 (1996) 451-461
20. Huggins J.W., Hsiang C.M., Cosgriff T.M., Guang M.Y., Smith J.I., Wu Z.O., LeDuc J.W., Zheng Z.M., Meegan J.M., and Wang Q.N. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J. Infect. Dis. 164 (1991) 1119-1127
21. Huggins J.W., Kim G.R., Brand O.M., and McKee Jr. K.T. Ribavirin therapy for Hantaan virus infection in suckling mice. J. Infect. Dis. 153 (1986) 489-497
22. Kumarapperuma S.C., Sun Y., Jeselnik M., Chung K., Parker W.B., Jonsson C.B., and Arterburn J.B. Structural effects on the phosphorylation of 3-substituted 1-beta-d-ribofuranosyl-1,2,4-triazoles by human adenosine kinase. Bioorg. Med. Chem. Lett. 17 (2007) 3203-3207
23. Lee H.W., Lee P.W., Baek L.J., Song C.K., and Seong I.W. Intraspecific transmission of Hantaan virus, etiologic agent of Korean hemorrhagic fever, in the rodent Apodemus agrarius. Am. J. Trop. Med. Hyg. 30 (1981) 1106-1112
24. Lopez N., Padula P., Rossi C., Lazaro M.E., and Franze-Fernandez M.T. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 220 (1996) 223-226
25. Maes P., Clement J., Gavrilovskaya I., and Van Ranst M. Hantaviruses: immunology, treatment, and prevention. Viral Immunol. 17 (2004) 481-497
26. Malinoski F., and Stollar V. Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110 (1981) 281-289
27. Martinez V.P., Bellomo C., San Juan J., Pinna D., Forlenza R., Elder M., and Padula P.J. Person-to-person transmission of Andes virus. Emerg. Infect Dis. 11 (2005) 1848-1853
28. Mertz G.J., Miedzinski L., Goade D., Pavia A.T., Hjelle B., Hansbarger C.O., Levy H., Koster F.T., Baum K., Lindemulder A., Wang W., Riser L., Fernandez H., and Whitley R.J. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. 39 (2004) 1307-1313
29. Minakawa N., Takeda T., Sasaki T., Matsuda A., and Ueda T. Nucleosides and nucleotides. 96. Synthesis and antitumor activity of 5-ethynyl-1-beta-d-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. J. Med. Chem. 34 (1991) 778-786
30. Narayana K., D'Souza U.J., and Seetharama Rao K.P. The genotoxic and cytotoxic effects of ribavirin in rat bone marrow. Mutat. Res. 521 (2002) 179-185
31. Padula P.J., Edelstein A., Miguel S.D., Lopez N.M., Rossi C.M., and Rabinovich R.D. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 241 (1998) 323-330
32. Peters C.J., Simpson G.L., and Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu. Rev. Med. 50 (1999) 531-545
33. Ramanathan H.N., Chung D.H., Plane S.J., Sztul E., Chu Y.K., Guttieri M.C., McDowell M., Ali G., and Jonsson C.B. Dynein-dependent transport of the Hantaan virus nucleocapsid protein to the endoplasmic reticulum-Golgi intermediate compartment. J. Virol. 81 (2007) 8634-8647
34. Schmaljohn C., and Hjelle B. Hantaviruses: a global disease problem. Emerg. Infect. Dis. 3 (1997) 95-104
35. Schmaljohn C.S., and Hooper J.W. Bunyaviridae: the viruses and their replication. In: Bernard D.M.K., Fields N., Bernard Roizman, Diane E., Griffin, Malcolm A., Martin, Robert A., Lamb, Peter M., Howley, Stephen E., and Straus (Eds). Fields Virology Vol.2 (2001), Lippincott Williams & Wilkins, Philadelphia, PA 1581-1633
36. Schmaljohn C.S., Hasty S.E., Harrison S.A., and Dalrymple J.M. Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J. Infect. Dis. 148 (1983) 1005-1012
37. Severson W.E., Schmaljohn C.S., Javadian A., and Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77 (2003) 481-488
38. Sidwell R.W., Huffman J.H., Khare G.P., Allen L.B., Witkowski J.T., and Robins R.K. Broad-spectrum antiviral activity of Virazole: 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177 (1972) 705-706
39. Sun Y., Chung D.H., Chu Y.K., Jonsson C.B., and Parker W.B. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5′-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob. Agents Chemother. 51 (2007) 84-88
40. Vitek C.R., Breiman R.F., Ksiazek T.G., Rollin P.E., McLaughlin J.C., Umland E.T., Nolte K.B., Loera A., Sewell C.M., and Peters C.J. Evidence against person-to-person transmission of hantavirus to health care workers. Clin. Infect. Dis. 22 (1996) 824-826
41. Wells R.M., Young J., Williams R.J., Armstrong L.R., Busico K., Khan A.S., Ksiazek T.G., Rollin P.E., Zaki S.R., Nichol S.T., and Peters C.J. Hantavirus transmission in the United States. Emerg. Infect. Dis. 3 (1997) 361-365
42. Yanagihara R., Amyx H.L., and Gajdusek D.C. Experimental infection with Puumala virus, the etiologic agent of nephropathia epidemica, in bank voles (Clethrionomys glareolus). J. Virol. 55 (1985) 34-38